Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease.
about
The relationship between COPD and lung cancerInhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoformsEvidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonistsAnti-inflammatory effect of a selective IkappaB kinase-beta inhibitor in rat lung in response to LPS and cigarette smoke.Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease.The p110α and p110β isoforms of class I phosphatidylinositol 3-kinase are involved in toll-like receptor 5 signaling in epithelial cellsCharacteristic DNA methylation profiles in peripheral blood monocytes are associated with inflammatory phenotypes of asthma.Nortriptyline reverses corticosteroid insensitivity by inhibition of phosphoinositide-3-kinase-δCigarette smoke extract induces COX-2 expression via a PKCalpha/c-Src/EGFR, PDGFR/PI3K/Akt/NF-kappaB pathway and p300 in tracheal smooth muscle cells.Pooled screening for antiproliferative inhibitors of protein-protein interactions.Combinations of indole-3-carbinol and silibinin suppress inflammation-driven mouse lung tumorigenesis by modulating critical cell cycle regulators.Corticosteroid insensitivity is reversed by formoterol via phosphoinositide-3-kinase inhibitionVEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma.Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasisA novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibitionPI3K gamma-deficient mice have reduced levels of allergen-induced eosinophilic inflammation and airway remodeling.Oxidative stress dependent microRNA-34a activation via PI3Kα reduces the expression of sirtuin-1 and sirtuin-6 in epithelial cells.Airway smooth muscle as a model for new investigative drugs in asthma.Anti-inflammatory activity of compounds isolated from Astragalus sinicus L. in cytokine-induced keratinocytes and skin.Challenges of treating asthma in people who smoke.Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.COX inhibitors for airway inflammation.Identifying and testing potential new anti-asthma agents.Inflammatory signalings involved in airway and pulmonary diseases.Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.Molecular control of PtdIns(3,4,5)P3 signaling in neutrophils.Decreased phosphatase PTEN amplifies PI3K signaling and enhances proinflammatory cytokine release in COPD.Novel approaches to the management of noneosinophilic asthma.Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease.Addressing corticosteroid insensitivity in adults with asthma.Theophylline action on primary human bronchial epithelial cells under proinflammatory stimuli and steroidal drugs: a therapeutic rationale approachThrombin induces ICAM-1 expression in human lung epithelial cells via c-Src/PDGFR/PI3K/Akt-dependent NF-κB/p300 activation.Heterogeneity of glucocorticoid resistance in patients with bronchial asthmaSingle-cell analysis of phosphoinositide 3-kinase and phosphatase and tensin homolog activationThe role of IFN-gamma in regulation of IFN-gamma-inducible protein 10 (IP-10) expression in lung epithelial cell and peripheral blood mononuclear cell co-cultures.Beyond GWAS in COPD: probing the landscape between gene-set associations, genome-wide associations and protein-protein interaction networks.Synergy of IL-27 and TNF-α in regulating CXCL10 expression in lung fibroblasts.Editorial: cell movement.Establishment of a structure-activity relationship of 1H-imidazo[4,5-c]quinoline-based kinase inhibitor NVP-BEZ235 as a lead for African sleeping sickness.Polymorphonuclear neutrophils move into the fast lane in chronic obstructive pulmonary disease.
P2860
Q26781337-AD3B6D65-95D1-4B03-9197-1E674F7C04AFQ28392359-D0D2FCDF-A1DA-4B16-8222-C578C5BB3187Q28588354-9596D0B5-7130-4AC7-A508-F0B3FA4FC88FQ33774669-CF8366D0-8832-40D1-882C-5FE80C36FDD8Q34103575-4B0036C4-E3E2-4495-8801-4BEC63E8434BQ34189683-6AEFC6D6-278B-438A-8109-50CDD683350EQ34212703-FB55E3E1-971F-4251-AD82-99B829D0120FQ34868133-43BE5B68-57E8-4461-9216-50DF9185641BQ35000264-A5A10138-3505-44F3-95EE-667D8E900CB8Q35930537-28C4F6DE-0295-4EE8-A8D7-8383EEBA4730Q36067911-C44891E3-A293-4CC9-8DB2-AE26D2861FAFQ36619748-21409868-845F-466E-8FEA-B40C42397965Q36715908-21AF2825-BDDA-48A8-A925-5C6F89638BB2Q36874745-8797A834-D582-4D8B-BA44-C1D1374DF9EBQ36965885-F6629D03-C9EB-404D-820A-EF68C0ABEA32Q37100515-C2BC7B27-7D14-4D90-8614-EF9F48856A1CQ37355584-29C7CB9D-8716-434A-A5F4-E73095987826Q37362604-95E6470E-0985-4455-946D-DC99F544A553Q37679431-3DB37E61-C904-43A3-9E80-3657CF380090Q37733518-2030E5DC-F60E-4ECD-A5D0-D95A0233AB77Q37886009-A71CF2DF-257B-4ACB-9FFF-24560CB12ECBQ37983125-C9930D22-9F85-41DE-9366-396F2A8B8FA0Q38014555-49D9B23F-7CB3-4048-BAED-568DE0443699Q38108292-0E1606E9-AFDE-4878-90C7-0A9784C52FAAQ38221107-B5DA3BDE-0CD4-46EA-865D-078086870FFEQ38313393-A141E50B-4C08-4F5C-94F3-003AF5C284F8Q38702978-7AB3CC76-F25E-43E8-9137-C8D2FC3F866CQ38756064-B3A87B69-BE8D-4ECA-9C98-A56BA8851D6EQ38882099-0B20BB96-E04E-4440-946E-CCDDE172B7A4Q38930984-19E2B8B4-5C0C-499C-B9DE-4A2A5113A064Q38972632-AF0BD325-0A76-4ED8-A38C-DFD07674B68EQ39026115-8527AE61-79CB-41FA-BE55-E945383C5261Q39546998-80C7EF33-5A87-4DF3-B374-A0CE0788A718Q39609521-7008DD0E-96D0-4113-B893-13D39517AD1DQ40053605-4F8CAC54-CFA3-4031-B360-B9D166047B08Q40114829-F5A7BFA8-07F6-41DF-9929-4981456DEED9Q42519574-C806E8DC-4ECD-4C32-A5C7-56DED5BB0986Q42703098-D4D45F15-817A-4656-8375-25B70BC22A29Q42736573-45CC63EF-32C9-4976-8DC8-9791B5F641D9Q42755614-CE004D8E-F78D-4922-A4E6-693D1B3B8142
P2860
Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Therapeutic potential of phosp ...... lammatory respiratory disease.
@ast
Therapeutic potential of phosp ...... lammatory respiratory disease.
@en
Therapeutic potential of phosp ...... lammatory respiratory disease.
@nl
type
label
Therapeutic potential of phosp ...... lammatory respiratory disease.
@ast
Therapeutic potential of phosp ...... lammatory respiratory disease.
@en
Therapeutic potential of phosp ...... lammatory respiratory disease.
@nl
prefLabel
Therapeutic potential of phosp ...... lammatory respiratory disease.
@ast
Therapeutic potential of phosp ...... lammatory respiratory disease.
@en
Therapeutic potential of phosp ...... lammatory respiratory disease.
@nl
P356
P1476
Therapeutic potential of phosp ...... flammatory respiratory disease
@en
P2093
Gaetano Caramori
Kazuhiro Ito
P356
10.1124/JPET.106.111674
P407
P577
2006-10-04T00:00:00Z